STERIS Stock Price Target and Analyst Ratings (NYSE:STE)

Analyst Price Target for STE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$214.25

▲ +2.32% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for STERIS in the last 3 months. The average price target is $214.25, with a high forecast of $230.00 and a low forecast of $200.00. The average price target represents a 2.32% upside from the last price of $209.39.

The #1 Way to Play the CBD Sector

From Investing Trends

A proprietary product line, unmatched distribution formula, and exponential growth potential in an explosive industry makes this company the top way to play the legal cannabis sector

Buy

The current consensus among 5 investment analysts is to buy stock in STERIS. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/28/2019

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/26/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/25/2020

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/24/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/22/2020

0 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/20/2021

0 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/21/2021

0 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/17/2021	KeyCorp	Boost Price Target	Overweight	$224.00 ➝ $227.00	Low	i
3/11/2021	KeyCorp	Boost Price Target	Overweight	$224.00 ➝ $227.00	Low	i
2/4/2021	KeyCorp	Upgrade	Sector Weight ➝ Overweight	$224.00	Low	i
1/20/2021	Raymond James	Reiterated Rating	Hold		Low	i
1/13/2021	Robert W. Baird	Boost Price Target	Outperform	$200.00 ➝ $230.00	Low	i
11/20/2020	Needham & Company LLC	Reiterated Rating	Hold		Medium	i Rating by Michael Matson at Needham & Company LLC
10/8/2020	JMP Securities	Boost Price Target		$180.00 ➝ $200.00	Low	i
10/7/2020	Stephens	Boost Price Target		$170.00 ➝ $200.00	Low	i
10/7/2020	Robert W. Baird	Boost Price Target	Outperform	$175.00 ➝ $200.00	Medium	i
10/6/2020	Needham & Company LLC	Reiterated Rating	Hold		Medium	i Rating by Michael Matson at Needham & Company LLC
9/1/2020	Robert W. Baird	Initiated Coverage	Outperform	$175.00	High	i
8/3/2020	Needham & Company LLC	Initiated Coverage	Hold		High	i Rating by Michael Matson at Needham & Company LLC
6/9/2020	Needham & Company LLC	Initiated Coverage	Hold		Medium	i
5/15/2020	Stephens	Boost Price Target	Overweight	$145.00 ➝ $170.00	Low	i
3/23/2020	Stephens	Lower Price Target	Overweight	$177.00 ➝ $145.00	High	i
2/12/2020	Northcoast Research	Reiterated Rating	Buy		Low	i Rating by D. Keiser at Northcoast Research
2/12/2020	Stephens	Boost Price Target	Overweight	$165.00 ➝ $177.00	High	i
5/22/2019	JMP Securities	Boost Price Target	Market Outperform	$135.00 ➝ $150.00	Low	i
5/15/2019	Stephens	Boost Price Target	Overweight	$135.00 ➝ $150.00	Low	i
5/15/2019	KeyCorp	Boost Price Target	Overweight	$135.00 ➝ $138.00	Low	i
2/14/2019	Stephens	Reiterated Rating	Buy	$135.00	Low	i
2/14/2019	JMP Securities	Reiterated Rating	Buy	$135.00	Low	i
12/6/2018	Sidoti	Boost Price Target	Buy ➝ Buy	$155.00 ➝ $157.00	Low	i
11/13/2018	KeyCorp	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $132.00	Low	i
8/9/2018	JMP Securities	Boost Price Target	Market Outperform ➝ Market Outperform	$113.00 ➝ $125.00	Low	i
8/9/2018	KeyCorp	Boost Price Target	Overweight ➝ Overweight	$115.00 ➝ $120.00	Low	i
8/9/2018	Stephens	Reiterated Rating	Buy	$125.00	Low	i
2/8/2018	KeyCorp	Reiterated Rating	Buy	$103.00	Medium	i
2/8/2018	Northcoast Research	Set Price Target	Buy	$102.00	Medium	i Rating by David Keiser at Northcoast Research
1/3/2018	Raymond James	Reiterated Rating	Outperform ➝ Market Perform	$100.00	High	i
11/9/2017	TD Securities	Boost Price Target	Buy	C$14.00 ➝ C$16.00	N/A	i
11/2/2017	KeyCorp	Reiterated Rating	Overweight	$91.00 ➝ $101.00	N/A	i
10/17/2017	KeyCorp	Reiterated Rating	Buy	$91.00	N/A	i Rating by Matthew Mishan at KeyCorp
10/16/2017	Raymond James	Boost Price Target	Outperform	$95.00 ➝ $100.00	N/A	i
8/9/2017	Raymond James	Boost Price Target	Outperform	$90.00 ➝ $95.00	Low	i
6/5/2017	Wellington Shields	Downgrade	Gradually Accumulate ➝ Hold		Low	i
5/3/2017	KeyCorp	Upgrade	Sector Weight ➝ Overweight	$89.00	High	i
11/30/2016	The Goldman Sachs Group	Initiated Coverage	Neutral	$71.00	N/A	i
11/4/2016	JMP Securities	Reiterated Rating	Buy		N/A	i
6/3/2016	Northcoast Research	Upgrade	Neutral ➝ Buy		N/A	i Rating by D. Keiser at Northcoast Research

(Data available from 4/21/2016 forward)

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The company was founded in 1985 and is based in Dublin, Ireland.

Today's Range

Now: $209.39

$207.94

$211.26

50 Day Range

MA: $190.24

$171.20

$208.63

52 Week Range

Now: $209.39

$138.66

$211.26

Volume

770,420 shs

Average Volume

624,975 shs

Market Capitalization

$17.87 billion

P/E Ratio

42.47

Dividend Yield

0.77%

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of STERIS?

The following equities research analysts have issued reports on STERIS in the last year: JMP Securities, KeyCorp, Needham & Company LLC, Raymond James, Robert W. Baird, Stephens, and Zacks Investment Research.
View the latest analyst ratings for STE.

What is the current price target for STERIS?

4 Wall Street analysts have set twelve-month price targets for STERIS in the last year. Their average twelve-month price target is $214.25, suggesting a possible upside of 2.3%. Robert W. Baird has the highest price target set, predicting STE will reach $230.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $200.00 for STERIS in the next year.
View the latest price targets for STE.

What is the current consensus analyst rating for STERIS?

STERIS currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STE will outperform the market and that investors should add to their positions of STERIS.
View the latest ratings for STE.

What other companies compete with STERIS?

Other companies that are similar to STERIS include Abbott Laboratories, Medtronic, Stryker, Intuitive Surgical, Becton, Dickinson and, Boston Scientific, Edwards Lifesciences, IDEXX Laboratories, Baxter International, DexCom, ResMed, Teleflex, Hologic, Insulet and Varian Medical Systems.

How do I contact STERIS's investor relations team?

STERIS's physical mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider's listed phone number is 353-1232-2000 and its investor relations email address is [email protected] The official website for STERIS is www.steris.com.

NYSE:STE - STERIS Stock Price Target and Predictions

Analyst Price Target for STE

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of STERIS?

What is the current price target for STERIS?

What is the current consensus analyst rating for STERIS?

What other companies compete with STERIS?

How do I contact STERIS's investor relations team?